- Investing Ideas
- U.K. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
U.K. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
3
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
3 companies
AstraZeneca
Market Cap: UK£236.9b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£152.30
7D
-0.6%
1Y
52.2%
Haleon
Market Cap: UK£32.5b
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
HLN
UK£3.64
7D
-2.4%
1Y
-2.8%
Bioventix
Market Cap: UK£94.0m
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.
BVXP
UK£18.50
7D
15.6%
1Y
-24.5%